ENDRA Life Sciences (NDRA) Operating Expenses (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported Operating Expenses for 11 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses rose 14.0% year-over-year to $1.5 million in Q2 2026; TTM through Jun 2026 was $6.6 million, a 22.46% decrease from a year earlier, with the FY2025 full-year figure at $5.8 million, down 46.72% from the prior year.
• Operating Expenses was $1.5 million for Q2 2026 at ENDRA Life Sciences, down from $2.2 million in the prior quarter.
• Over five years, Operating Expenses peaked at $4.3 million in Q4 2024 and troughed at $1.3 million in Q2 2025.
• A 5-year average of $2.4 million and a median of $2.5 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses soared 194.75% in 2024 and sank 62.25% in 2025, its largest moves.
• Over 5 years, Operating Expenses stood at $3.3 million in 2022, then sank by 56.0% to $1.5 million in 2023, then soared by 194.75% to $4.3 million in 2024, then slumped by 62.25% to $1.6 million in 2025, then dropped by 8.56% to $1.5 million in 2026.
• The last three Operating Expenses figures came in at $1.5 million (Q2 2026), $2.2 million (Q1 2026), and $1.6 million (Q4 2025), per Business Quant data.